gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Spen homolog, transcriptional regulator

MINT, SHARP, MINT1, X11
This gene encodes a hormone inducible transcriptional repressor. Repression of transcription by this gene product can occur through interactions with other repressors, by the recruitment of proteins involved in histone deacetylation, or through sequestration of transcriptional activators. The product of this gene contains a carboxy-terminal domain that permits binding to other corepressor proteins. This domain also permits interaction with members of the NuRD complex, a nucleosome remodeling protein complex that contains deacetylase activity. In addition, this repressor contains several RNA recognition motifs that confer binding to a steroid receptor RNA coactivator; this binding can modulate the activity of both liganded and nonliganded steroid receptors. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, p16, MLH1, HAD, POLYMERASE
Papers using MINT antibodies
Membrane microdomain switching: a regulatory mechanism of amyloid precursor protein processing
Supplier
Nukina Nobuyuki et al., In The Journal of Cell Biology, 2001
... Rabbit anti-X11 (Santa Cruz Biotechnology, Inc.) was affinity purified ...
Papers on MINT
Confirmation of the Factor Structure and Measurement Invariance of the Children's Scale of Hostility and Aggression: Reactive/Proactive in Clinic-Referred Children with and without Autism Spectrum Disorder.
New
Aman et al., Columbus, United States. In J Child Adolesc Psychopharmacol, Feb 2016
In this study, we confirm the factor structure of the Children's Scale for Hostility and Aggression: Reactive/Proactive (C-SHARP) and demonstrate measurement invariance (consistent performance across clinical groups) between clinic-referred groups with and without autism spectrum disorder (ASD).
The p38 MAP kinase pathway modulates the hypoxia response and glutamate receptor trafficking in aging neurons.
New
Rongo et al., United States. In Elife, Feb 2016
Mutants lacking p38 MAPK components pmk-1 or sek-1 resemble mutants lacking the hypoxia response component and prolyl hydroxylase egl-9, with impaired subcellular localization of Mint orthologue LIN-10, internalization of glutamate receptor GLR-1, and depression of GLR-1-mediated behaviors.
Collocated comparisons of continuous and filter-based PM2.5 measurements at Fort McMurray, Alberta, Canada.
New
Percy et al., Canada. In J Air Waste Manag Assoc, Feb 2016
Both the Tapered Element Oscillating Microbalance (TEOM), operated at 40°C (i.e., TEOM40), and Synchronized Hybrid Ambient Real-time Particulate (SHARP, a Federal Equivalent Method [FEM]), were compared with a Partisol PM2.5 U.S. Federal Reference Method (FRM) sampler.
Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial.
New
O'Hare et al., Seattle, United States. In Adv Chronic Kidney Dis, Jan 2016
The Study of Heart and Renal Protection (SHARP) found that treatment with ezetemibe and low-dose simvastatin reduced the incidence of major atherosclerotic events in patients with kidney disease.
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
New
SHARP Collaborative Group et al., Oxford, United Kingdom. In Am J Kidney Dis, Dec 2015
BACKGROUND: Simvastatin, 20mg, plus ezetimibe, 10mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown.
Systemic therapies for hepatocellular carcinoma.
Review
New
Huang et al., Tianjin, China. In Drug Discov Ther, Oct 2015
According to the results of SHARP and ORIENTAL study, sorafenib became the standard first-line therapy since 2008 because of nearly three months of survival improvement in patients with advanced HCC.
The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3.
New
Impact
Guttman et al., Pasadena, United States. In Nature, Jun 2015
We identify ten proteins that specifically associate with Xist, three of these proteins--SHARP, SAF-A and LBR--are required for Xist-mediated transcriptional silencing.
Practical recommendations for the management of hyperlipidemia.
Review
New
Julius et al., Dresden, Germany. In Atheroscler Suppl, May 2015
In the SHARP Study the combination of simvastatin plus ezetimibe was effective in reducing cardiovascular events in patients with severe renal insufficiency (especially before dialysis but also in dialysis dependent patients).
Safety and efficacy of statins in patients with end-stage renal disease.
Review
Moore et al., Detroit, United States. In Ann Pharmacother, 2013
The 4D and AURORA trials failed to show a benefit with statin therapy, and the SHARP trial, although positive, also included patients with earlier stages of chronic kidney disease.
[An inhibitor of intestinal cholesterol transporter].
Review
Sano, In Nihon Rinsho, 2013
In SHARP(Study of Heart and Renal Protection) study, patients with severe renal disease were allocated either for statin alone group or combination therapy group with statin and ezetimibe.
Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials.
Review
Chen et al., Kao-hsiung, Taiwan. In Rev Diabet Stud, 2012
However, a large clinical study, the Study of Heart and Renal Protection (SHARP), does not support that statins could reduce ESRD in CKD.
Autoinhibition of Mint1 adaptor protein regulates amyloid precursor protein binding and processing.
GeneRIF
Ho et al., Boston, United States. In Proc Natl Acad Sci U S A, 2012
an autoinhibitory mechanism in Mint1 is important for regulating APP processing and may provide novel therapies for Alzheimer's disease
The molecular basis of the Caskin1 and Mint1 interaction with CASK.
GeneRIF
Bowie et al., Los Angeles, United States. In J Mol Biol, 2011
Study identified the conserved binding site for the peptide on the CASK calmodulin kinase domain. A related EPIWVMRQ peptide from Mint1 was also discovered to be sufficient for binding.
RNA steady-state defects in myotonic dystrophy are linked to nuclear exclusion of SHARP.
GeneRIF
Reddy et al., Los Angeles, United States. In Embo Rep, 2011
These results demonstrate a role for the inactivation of SHARP transcription in DM1 biology.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Impact
SHARP Investigators et al., Oxford, United Kingdom. In Lancet, 2011
The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.
Transcriptional repression in the Notch pathway: thermodynamic characterization of CSL-MINT (Msx2-interacting nuclear target protein) complexes.
GeneRIF
Kovall et al., Cincinnati, United States. In J Biol Chem, 2011
MINT forms a high affinity complex with CSL; the domains of MINT and CSL that are necessary and sufficient for complex formation are delineated
Signaling via amyloid precursor-like proteins APLP1 and APLP2.
GeneRIF
Bredesen et al., Novato, United States. In J Alzheimers Dis, 2010
Transcriptional co-activators Taz and Yap mediate signaling via the amyloid beta protein precursor paralogues APLP1 and APLP2 through interactions with Mint1 and Mint3.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Impact
Guan et al., Taipei, Taiwan. In Lancet Oncol, 2009
Taken together with data from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) trial, sorafenib seems to be an appropriate option for the treatment of advanced hepatocellular carcinoma.
Analyses of cancer data from three ezetimibe trials.
Impact
Califf et al., Oxford, United Kingdom. In N Engl J Med, 2008
METHODS: We compared the results of a hypothesis-generating analysis of the incidence of cancer in the SEAS trial of ezetimibe plus simvastatin in 1873 patients (mean follow-up after ezetimibe or matching placebo was begun, 4.1 years) with a hypothesis-testing analysis of cancer data from the two large ongoing trials of this regimen: the Study of Heart and Renal Protection (SHARP) (NCT00125593) with 9264 patients (mean follow-up, 2.7 years) and the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) (NCT00202878), currently with 11,353 patients (mean follow-up, 1.0 year).
Regulation of lymphocyte development by Notch signaling.
Review
Impact
Honjo et al., Moriyama, Japan. In Nat Immunol, 2007
Here we highlight parallels in the developmental regulation of mammalian lymphocytes and the D. melanogaster nervous system through Notch cooperation with the transcriptional regulators RBP-J (Su(H)), MINT (Hairless) and E2A (Ac-Sc-Da).
share on facebooktweetadd +1mail to friends